Crossref
Expert opinion on the use of zanubrutinib in first-line treatment for chronic lymphocytic leukemia
Acta Haematologica Polonica · 04.11.2026
DOI: 10.5603/ahp.114616 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Haematologica Polonica, online erschienen am 04.11.2026. Verfasst von Bartosz Puła und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Puła, B., Jamroziak, K., Giannopoulos, K., Wróbel, T., Gil, L., Plisko, R., Hus, I., & Robak, T. (2026). Expert opinion on the use of zanubrutinib in first-line treatment for chronic lymphocytic leukemia. Acta Haematologica Polonica. https://doi.org/10.5603/ahp.114616
Vancouver
Puła B, Jamroziak K, Giannopoulos K, Wróbel T, Gil L, Plisko R, et al. Expert opinion on the use of zanubrutinib in first-line treatment for chronic lymphocytic leukemia. Acta Haematologica Polonica. 2026. doi:10.5603/ahp.114616
BibTeX
@article{Pua2026,
author = {Puła, Bartosz and Jamroziak, Krzysztof and Giannopoulos, Krzysztof and Wróbel, Tomasz and Gil, Lidia and Plisko, Robert and Hus, Iwona and Robak, Tadeusz},
title = {Expert opinion on the use of zanubrutinib in first-line treatment for chronic lymphocytic leukemia},
journal = {Acta Haematologica Polonica},
year = {2026},
doi = {10.5603/ahp.114616}
}
EUVIMED